GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK PLC (LSE:GSK, NYSE:GSK) said it was calling an early halt to trials of a new treatment for uncomplicated urinary tract infection (uUTI) because it has already proved its efficacy. An Independent Data Monitoring Committee (IDMC) recommended stopping the EAGLE-2 and EAGLE-3 phase III trials for gepotidacin as they had already met the primary endpoint without any safety concerns.

GSK to submit urinary infection treatment for approval after trial success

GSK reported strong third-quarter earnings and raised its forecast for 2022. However worries about Zantac litigation kept investors on edge.

GSK vaccine for older adults granted FDA priority review

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment

GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up

GSK plc (NYSE:GSK ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Iain Mackay - CFO & Executive Director Conference Call Participants James Gordon - JPMorgan Chase & Co. Simon Baker - Redburn Richard Parkes - BNP Paribas Exane Emmanuel Papadakis - Deutsche Bank Stephen Scala - Cowen and Company Peter Welford - Jefferies Timothy Anderson - Wolfe Research Emily Field - Barclays Bank Kerry Holford - Berenberg Michael Leuchten - UBS Graham Parry - Bank of America Merrill Lynch Andrew Baum - Citi Jo Walton - Crédit Suisse Keyur Parekh - Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Analyst Call for the GSK Third Quarter 2022 Results. I will now hand you over to Nick Stone, Head of Global Investor Relations, who will introduce today's session.

GSK plc (GSK) Q3 2022 Earnings Call Transcript

GSK stock jumped Wednesday after the company beat third-quarter forecasts due to strength from specialty medicines and Shingrix. The post GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat appeared first on Investor's Business Daily.

GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat

GSK PLC (LSE:GSK, NYSE:GSK)'s third quarter results beat City expectations according to broker UBS which said turnover of £7,829mln was 7% ahead of consensus with adjusted operating profit of £2,605mln, 13% above expectations and adjusted EPS of 46.9p, 17% ahead of the forecast of 40.1p. Vaccines beat forecasts by 3% driven by Shingrix sales of £760mln (11% above consensus) while the HIV portfolio with sales of £1,486m was slightly (1%) ahead, the broker said in a note following the numbers.

GSK results top City forecasts, UBS sees consensus EPS forecasts rising 3%

Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

GSK became a pure-play pharmaceutical company after spinning off its consumer-health arm earlier this year.

GSK Raises Guidance as Earnings Beat Helps Sure Up Position of CEO

GSK raised its full year guidance for the second time in three months as soaring sales of its shingles vaccine, Shingrix, drove bumper third quarter results which comfortably topped City expectations. The FTSE 100 listed company reported a 9% increase in constant currency quarter three sales to £7.83bn, ahead of City expectations of £7.32bn, with adjusted earnings per share of 46.9p, above forecasts of 40.1p.

GSK lifts guidance again as bumper third quarter results top City forecasts

GSK PLC on Wednesday raised its guidance for the full year and posted rising sales for the third quarter that beat expectations.

GSK lifts 2022 view after third quarter sales of $8.99 billion beat forecasts

GSK eclipsed analyst estimates for third-quarter earnings on Wednesday, driven by higher sales of its blockbuster shingles vaccine Shingrix, and raised its 2022 forecast for the second time in four months.

GSK lifts earnings view again after forecast-beating quarter

If GSK PLC (LSE:GSK, NYSE:GSK) (GSK PLC (LSE:GSK, NYSE:GSK), GSK PLC (LSE:GSK, NYSE:GSK)) hoped spinning off its consumer household arm Haleon in July would lead to an instant re-rating to a supercharged US pharma level, it must be sorely disappointed so far. Shares have barely moved either way since the separation, but next week's results should give a clearer picture of where new GSK sits in the pharma league table (as explored more fully in the GSK preview).

Wednesday's Agenda- Next to iron out latest figures, GSK expecting disappointing results

GlaxoSmithKline (LON: GSK) share price has made a strong rebound recently as investors buy the company's dip. The shares jumped to a high of 1,433p on Monday, which was the highest level since August 11 of this year.

GSK share price gains momentum ahead of earnings: is it a buy?

China has blocked British drugmaker GSK plc from participating in its national drug procurement programme from Oct. 31, 2022 to April 29, 2024, state television CCTV reported on Monday.

China bars GSK from national drug bulk-buy programme over drug irregularities

AP Moller - Maersk A/S

Bayer AG

Himax Tech

Ituran Location & Control

Bank of N.T. Butterfield & Son

Schneider Electric SE

Sibanye Stillwater

Vale S.A.

Telefonica Brasil

Vodafone Group

Subscribers to my Dividend Dogcatcher Marketplace (behind the SA paywall) know my Viital portfolio (#VII) stocks are “selected based-on gains, yield, momentum, price-upside, dividend-history, analyst-interest, special-market qualities, and dividend-safety.”. By yield, HIMX topped-all Viital eX-US candidates. Top-ten Yields from NTB, EMBVF, BCE, SBSW, GSK, VOD, VALE, CRARF, AMKBY, and HIMX averaged 9.94%.

15 Top October Ex-U.S. Dividend Dogs, Which One To Buy?

GSK is on course to have its new RSV vaccine fast-tracked in Europe after the EMA validated its marketing application based in impressive results from a recent phase III trial. That study showed 83% efficacy against respiratory syncytial virus-lower respiratory tract disease in adults aged 60 years and above with a favourable safety profile (read more).

GSK's vaccine for RSV on course to be fast-tracked in Europe

If GSK hoped spinning off its consumer household arm Haleon in July would lead to an instant re-rating to a supercharged US pharma level, it must be sorely disappointed so far. Shares have barely moved either way since the separation, but next week's results should give a clearer picture of where new GSK sits in the pharma league table.

GSK needs to confirm upward curve in next week's update

GSK PLC (LSE:GSK, NYSE:GSK) has reported that a US Food and Drugs Administration (FDA) committee voted that the benefits of its drug, daprodustat outweighed risks for adult dialysis patients with anaemia of chronic kidney disease (CKD), but not for those not undergoing dialysis. The company said the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 13 to three in favour of saying the drug benefitted patients on dialysis, but five to 11 against for non-dialysis patients.

GSK reports mixed outcome from meeting with US Food and Drug Administration

GSK Plc came closer to securing its first drug approval since its consumer health spin-off in July as an expert panel of the U.S. health regulator backed an approval for its drug to treat anemia in some patients with chronic kidney disease (CKD).

New GSK closer to first U.S. approval with anemia drug for patients on dialysis

GSK is a research-based pharmaceutical company, which means it invents new drugs, brings them to market and sells them all over the world. GSK was previously known as GlaxoSmithKline and it was born in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham.

Is GSK A Good Choice For Dividend Investors?

Citibank said it still expects the outcome of the Daubert (evidence admissibility) hearings into Zantac to be favourable to the defendants including GlaxoSmithKline and Sanofi after the initial proceedings. “We anticipate investor's expectations for liabilities to be meaningfully pared back pending the anticipated Daubert ruling,” the US bank said in a note.

GSK to get boost if Zantac ruling reduces liability fears, reckons Citi

Bank of America

General Electric

Inmode Ltd

JPMorgan Chase & Co

El Pollo Loco

Splunk

I know that saying “This time could be different” is dangerous. But still, when it comes to U.S. stocks, I believe that this time could be different and that the long-awaited (by me, at least) bull market may have begun.

7 Quality Stocks Selling at a Discount as Q4 Kicks Off

Pfizer

GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.

GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults

There is a “value disconnect” in GSK PLC (LSE:GSK, NYSE:GSK) shares, said broker Shore Capital, after “hugely positive” detailed data was published on results from the Phase III clinical trial of its respiratory syncytial virus (RSV) vaccine candidate.

GSK shares trading with 'value disconnect', says broker

The British pharmaceutical giant said its experimental vaccine against respiratory syncytial virus sharply reduced the risk of disease in a key trial, paving the way for a contest with Pfizer Inc. in what the companies expect to be a lucrative market.

News for GlaxoSmithKline Stock (GSK)